Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Frontiers in Medicine Pub Date : 2025-09-22 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1654271

Shomi Oka, Takashi Higuchi, Kota Shimada, Misuzu Fujimori, Atsushi Hashimoto, Akiko Komiya, Koichiro Saisho, Norie Yoshikawa, Michita Suzuki, Toshihiro Matsui, Naoshi Fukui, Kiyoshi Migita, Shigeto Tohma, Hiroshi Furukawa

{"title":"Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema.","authors":"Shomi Oka, Takashi Higuchi, Kota Shimada, Misuzu Fujimori, Atsushi Hashimoto, Akiko Komiya, Koichiro Saisho, Norie Yoshikawa, Michita Suzuki, Toshihiro Matsui, Naoshi Fukui, Kiyoshi Migita, Shigeto Tohma, Hiroshi Furukawa","doi":"10.3389/fmed.2025.1654271","DOIUrl":null,"url":null,"abstract":"Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-Porphyromonas gingivalis (P. gingivalis) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-P. gingivalis Ab levels. However, amounts of anti-P. gingivalis Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-P. gingivalis Ab in cases of RA with CLD.Methods: Anti-P. gingivalis lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay.Results: Anti-P. gingivalis LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (P = 0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×103U/mL] vs. 403.5 ± 2552.7 [×103U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-P. gingivalis LPS Ab amounts were increased in RA without CLD (P = 0.0412) compared with healthy controls (77.6 ± 183.7 [×103U/mL]).Conclusion: Anti-P. gingivalis LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1654271"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1654271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-Porphyromonas gingivalis (P. gingivalis) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-P. gingivalis Ab levels. However, amounts of anti-P. gingivalis Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-P. gingivalis Ab in cases of RA with CLD.

Methods: Anti-P. gingivalis lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay.

Results: Anti-P. gingivalis LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (P = 0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×10³U/mL] vs. 403.5 ± 2552.7 [×10³U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-P. gingivalis LPS Ab amounts were increased in RA without CLD (P = 0.0412) compared with healthy controls (77.6 ± 183.7 [×10³U/mL]).

Conclusion: Anti-P. gingivalis LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.

Abstract Image

查看原文本刊更多论文

类风湿关节炎合并肺气肿患者抗牙龈卟啉单胞菌脂多糖抗体的研究。

目的：慢性肺部疾病（肺气肿[EMP]、气道疾病、肺间质性疾病）可使类风湿关节炎（RA）并发关节外表现。抗牙龈卟啉单胞菌（P. gingivalis）抗体（Ab）已被用于牙周病的诊断，RA患者表现为抗p增高。牙龈Ab水平。然而，抗p。类风湿性关节炎合并慢性肺部疾病（CLD）的龈菌抗体尚不清楚。我们测量了反p。在类风湿性关节炎合并CLD的病例中使用gingivalis Ab。方法:Anti-P。采用酶免疫法测定RA患者血清中牙龈脂多糖（LPS） Ab的含量。结果:Anti-P。有EMP的RA患者牙龈LPS Ab水平显著低于无CLD的RA患者（P = 0.0190，平均±标准差[SD]， 32.7±64.2 [×103U/mL] vs. 403.5±2552.7 [×103U/mL]）。多元逻辑回归分析显示了这种关联的独立性。Anti-P。与健康对照组（77.6±183.7 [×103U/mL]）相比，无CLD的RA组牙龈LPS Ab含量升高（P = 0.0412）。结论:Anti-P。与无CLD的RA相比，EMP组RA的牙龈LPS Ab水平较低。瓜氨酸肽主要产生于有EMP的RA的肺部和无CLD的RA的口腔，提示RA的异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world